BIO-TECHNE TO PRESENT AT THE BARCLAYS GLOBAL HEALTHCARE CONFERENCE

Bio-Techne Corporation (NASDAQ: TECH) announced that Jim Hippel, Executive Vice President and CFO, will present at the Barclays Global Healthcare Conference on March 14, 2023, at 2:35 p.m. EDT.

Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) announced that Jim Hippel, Executive Vice President and CFO, will present at the Barclays Global Healthcare Conference on March 14, 2023, at 2:35 p.m. EDT. A live webcast can be accessed on Bio-Techne's Investor Relations website.

Bio-Techne is a leader in developing high-quality purified proteins and reagents, generating approximately $1.1 billion in net sales in fiscal 2022. The company's extensive portfolio supports biomedical research and diagnostics, enhancing drug discovery and clinical testing.

Argus Session date unavailable

-2.82% session move Open Argus

Details

News Market Reaction – TECH

The recorded move for TECH in the trading session of this news was -2.82%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MINNEAPOLIS, March 10, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Barclays Global Healthcare Conference on Tuesday, March 14, 2023, at 2:35 p.m. EDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, T-Cell activation and gene editing technologies. Bio-Techne's product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and custom assay development on dedicated clinical instruments. Bio-Techne's genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx^® Prostate test for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne's Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2022 and has approximately 3,000 employees worldwide.

Contact:	David Clair, Vice President, Investor Relations & Corporate Development
	david.clair@bio-techne.com
	612-656-4416

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-barclays-global-healthcare-conference-301768463.html

SOURCE Bio-Techne Corporation

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Bio-Techne present at the Barclays Global Healthcare Conference?

Bio-Techne will present on March 14, 2023, at 2:35 p.m. EDT.

Who will represent Bio-Techne at the Barclays Global Healthcare Conference?

Jim Hippel, Executive Vice President and CFO, will represent Bio-Techne.

Where can I watch Bio-Techne's presentation live?

The presentation can be viewed live on Bio-Techne's Investor Relations website.

What were Bio-Techne's net sales in fiscal 2022?

Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2022.

What does Bio-Techne Corporation specialize in?

Bio-Techne specializes in developing high-quality purified proteins and reagent solutions for biomedical research.